Advisor Resource Council Gilead Sciences, Inc. Transaction History

Advisor Resource Council

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Jan 12, 2024	BUY	$73.27 - $83.09 $234,976 - $266,469	3,207 New	3,207 $259,000
Q1 2023 Apr 25, 2023	BUY	$77.31 - $88.08 $227,523 - $259,219	2,943 New	2,943 $244,000
Q2 2022 Jul 27, 2022	SELL	$57.72 - $65.01 $498,931 - $561,946	-8,644 Reduced 59.07%	5,990 $371,000
Q1 2022 Apr 20, 2022	SELL	$57.92 - $72.58 $252,762 - $316,739	-4,364 Reduced 22.97%	14,634 $870,000
Q4 2021 Feb 11, 2022	BUY	$64.88 - $73.64 $239,926 - $272,320	3,698 Added 24.17%	18,998 $1.38 Million
Q3 2021 Nov 16, 2021	SELL	$67.69 - $73.03 $355,507 - $383,553	-5,252 Reduced 25.55%	15,300 $1.07 Million
Q2 2021 Aug 19, 2021	BUY	$63.47 - $69.35 $1.21 Million - $1.33 Million	19,136 Added 1351.41%	20,552 $1.42 Million
Q2 2021 Aug 13, 2021	BUY	$63.47 - $69.35 $89,873 - $98,199	1,416 New	1,416 $97,000

1,893

1.02B

12M

9.04M

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $110B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

Get notified when there are updates to the investment portfolio of Advisor Resource Council, based on Form 13F filings with the SEC.

Stay updated on Advisor Resource Council with notifications on news.